Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy

INTRODUCTION: This is the first description of safety data for intravenous onasemnogene abeparvovec, the only approved systemically administered gene-replacement therapy for spinal muscular atrophy. OBJECTIVE: We comprehensively assessed the safety of intravenous onasemnogene abeparvovec from precli...

Descripción completa

Detalles Bibliográficos
Autores principales: Day, John W., Mendell, Jerry R., Mercuri, Eugenio, Finkel, Richard S., Strauss, Kevin A., Kleyn, Aaron, Tauscher-Wisniewski, Sitra, Tukov, Francis Fonyuy, Reyna, Sandra P., Chand, Deepa H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473343/
https://www.ncbi.nlm.nih.gov/pubmed/34383289
http://dx.doi.org/10.1007/s40264-021-01107-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473343/
https://www.ncbi.nlm.nih.gov/pubmed/34383289
http://dx.doi.org/10.1007/s40264-021-01107-6

Ejemplares similares